Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement

12/23/22 4:02:00 PM ET

Medicinal Chemicals and Botanical Products

Health Care

Get the next $MTCR alert in real time by email

Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities.

Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www.sec.gov and on Metacrine's website under the heading "Investors."

Get the next $MTCR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MTCR

Date	Price Target	Rating	Analyst
10/22/2021	$2.50	Outperform → Sector Perform	RBC Capital Mkts
10/22/2021	$19.00 → $1.00	Buy → Hold	Canaccord Genuity
10/22/2021	$14.00 → $2.00	Buy → Hold	Jefferies
10/22/2021		Buy → Neutral	HC Wainwright & Co.

More analyst ratings

12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers HTG Molecular Diagnostics (NASDAQ:HTGM) shares moved upwards by 33.0% to $6.01 during Wednesday's after-market session. This security traded at a volume of 323.6K shares come close, making up 21.6% of its average volume over the last 100 days. The company's market cap stands at $6.1 million. Lannett (NYSE:LCI) shares rose 15.74% to $0.62. The market value of their outstanding shares is at $26.2 million. As per the press release, Q2 earnings came out today. Align Tech (NASDAQ:ALGN) shares rose 15.03% to $325.0. At the close, Align Tech's trading volume reached 121.5K shares. This is 11.8% of its average volume over the last 100 days. The company's market cap stands at $25.3 billion
2/1/23 4:30:58 PM ET
$ADIL
$ALGN
$BGXX
$CALA
Biotechnology: Pharmaceutical Preparations
Health Care
Industrial Specialties
Medicinal Chemicals and Botanical Products
Metacrine Says President, CEO, Secretary, Principal Executive Officer Preston Klassen Was Terminated From Positions, Effective Feb. 1
-Reuters
1/24/23 5:19:03 PM ET
$MTCR
Medicinal Chemicals and Botanical Products
Health Care
Metacrine, Equillium And 3 Stocks To Watch Heading Into Tuesday
With US stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. (NASDAQ:EQ) mutually agreed to terminate definitive merger agreement. Metacrine shares jumped 5.4% to $0.4551 in after-hours trading, while Equillium shares dropped 6.3% to close at $0.89 on Friday. Oragenics, Inc. (NYSE:OGEN) disclosed a 1-for-60 reverse stock split. Oragenics shares dipped 6.7% to close at $0.1450 on Friday. Check out our premarket coverage here Pintec Technology Holdings Limited (NASDAQ:PT) reported that its total revenues dropped by 56.53% year-over-year to RMB39.82 million ($5.93 mi
12/27/22 4:12:07 AM ET
$EQ
$MTCR
$OGEN
$PT
Biotechnology: Pharmaceutical Preparations
Health Care
Medicinal Chemicals and Botanical Products
Computer Software: Programming Data Processing

$MTCR
Press Releases

Fastest customizable press release news feed in the world

Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement
LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www.sec.gov and on Metacrine's website under the heading "Investors." About Metacrine Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies t
12/23/22 4:01:00 PM ET
$MTCR
Medicinal Chemicals and Botanical Products
Health Care
Metacrine Reports Third-Quarter 2022 Results
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. "We made great progress during the quarter in advancing our proposed merger with Equillium," said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. "We believe that Equillium has demonstrated compelling clinical data in Lupus Nephritis and has an exciting pipeline of clinical programs with multiple upcoming data catalysts and potential value inflection events. Equillium is led by an accomplished leadership
11/14/22 4:38:48 PM ET
$MTCR
Medicinal Chemicals and Botanical Products
Health Care
Equillium to Acquire Metacrine in All-Stock Transaction
Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.
9/6/22 4:00:00 PM ET
$EQ
$MTCR
Biotechnology: Pharmaceutical Preparations
Health Care
Medicinal Chemicals and Botanical Products

Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement

Chat with this insight

Recent Analyst Ratings for
$MTCR

$MTCR
Financials

Live finance-specific insights

Equillium to Acquire Metacrine in All-Stock Transaction

$MTCR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Klassen Preston

SEC Form 4: York Michael sold $44,331 worth of shares (107,054 units at $0.41), decreasing direct ownership by 51% to 103,499 units (tax withholding)

SEC Form 4: Klassen Preston sold $157,266 worth of shares (380,605 units at $0.41), decreasing direct ownership by 41% to 541,905 units (tax withholding)

$MTCR
Leadership Updates

Live Leadership Updates

Metacrine Announces Resignation of Chief Medical Officer

Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors

$MTCR
Market Insights

Live Market Insights

12 Health Care Stocks Moving In Wednesday's After-Market Session

Metacrine Says President, CEO, Secretary, Principal Executive Officer Preston Klassen Was Terminated From Positions, Effective Feb. 1

Metacrine, Equillium And 3 Stocks To Watch Heading Into Tuesday

$MTCR
SEC Filings

SEC Form 15-12G filed by Metacrine Inc.

Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders

SEC Form S-8 POS filed by Metacrine Inc.

$MTCR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$MTCR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)

SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)

SEC Form SC 13G filed by Metacrine Inc.

Metacrine downgraded by RBC Capital Mkts with a new price target

Metacrine downgraded by Canaccord Genuity with a new price target

Metacrine downgraded by Jefferies with a new price target

$MTCR
Press Releases

Fastest customizable press release news feed in the world